Continuous Renal Replacement Therapy for a Patient with Severe COVID-19
Author(s) -
Daisuke Katagiri,
Masahiro Ishikane,
Tatsunori Ogawa,
Noriko Kinoshita,
Harutaka Katano,
Tadaki Suzuki,
Takashi Fukaya,
Fumihiko Hinoshita,
Norio Ohmagari
Publication year - 2020
Publication title -
blood purification
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.686
H-Index - 57
eISSN - 1421-9735
pISSN - 0253-5068
DOI - 10.1159/000508062
Subject(s) - renal replacement therapy , acute kidney injury , medicine , intensive care medicine , covid-19 , dialysis , respiratory failure , disease , outbreak , infectious disease (medical specialty) , virology
The outbreak of coronavirus disease 2019 (COVID-19) is a global health threat. It is a respiratory disease, and acute kidney injury (AKI) is rare; however, if a patient develops severe AKI, renal replacement therapy (RRT) should be considered. Recently, we had a critically ill COVID-19 patient who developed severe AKI and needed continuous RRT (CRRT). To avoid the potential risk of infection from CRRT effluents, we measured severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genetic material in the effluents by qRT-PCR, and low copy numbers of the viral genome were detected. Due to unstable hemodynamic status in critically ill patients, CRRT should be the first choice for severe AKI in COVID-19 patients. We suggest prevention of clinical infection and control during administration of RRT in the acute phase of COVID-19 patients with AKI or multiple organ failure.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom